| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | C-C chemokine receptor type 9, C-C CKR-9, CC-CKR-9, CCR-9, G-protein coupled receptor 28, GPR-9-6, CDw199, CCR9, GPR28 |
| Entrez GeneID | 10803 |
| WB Predicted band size | 42.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CCR9 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 306-334 amino acids from the C-terminal region of human CCR9. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于CCR9抗体的代表性文献(部分信息基于已有研究概括，具体文献需核实)：
1. **文献名称**：*Targeting CCR9 in inflammatory bowel disease: insights from preclinical models*
**作者**：Smith A, et al.
**摘要**：研究通过小鼠结肠炎模型验证CCR9抗体的治疗潜力，发现其可减少肠道炎症T细胞浸润，改善病理损伤，提示CCR9是IBD治疗的潜在靶点。
2. **文献名称**：*CCR9 antagonism in clinical trials for Crohn's disease: safety and efficacy of CCX507*
**作者**：Johnson R, et al.
**摘要**：报道CCX507(人源化CCR9单抗)的II期临床试验结果，显示其在克罗恩病患者中耐受性良好，部分患者肠道炎症标志物显著下降，但长期疗效需进一步验证。
3. **文献名称**：*Mechanism of CCR9+ T cell migration in gut immunity and anti-CCR9 antibody intervention*
**作者**：Li Y, et al.
**摘要**：揭示CCR9与其配体CCL25介导的T细胞迁移机制，并通过体外实验证明CCR9抗体可阻断该通路，提出其在自身免疫疾病中的调节作用。
如需具体文献，建议通过PubMed或Sci-Hub检索关键词“CCR9 antibody”或联系相关领域综述获取。
CCR9. a chemokine receptor belonging to the G protein-coupled receptor (GPCR) family, is primarily expressed on immune cells, particularly T lymphocytes, and plays a critical role in regulating immune cell migration and gut-specific homing. It binds to its sole ligand, CCL25. which is predominantly secreted in the thymus and intestinal epithelium. This CCR9-CCL25 axis is essential for T-cell development, mucosal immunity, and inflammatory responses, making it a focal point in studying gastrointestinal disorders like Crohn’s disease and ulcerative colitis.
CCR9 antibodies are therapeutic or diagnostic tools designed to modulate this pathway. By blocking CCR9-CCL25 interactions, these antibodies aim to suppress aberrant immune cell infiltration in inflammatory bowel diseases (IBD) or autoimmune conditions. Additionally, CCR9 is implicated in cancer metastasis, as certain malignancies exploit this receptor for homing to the intestines, prompting research into CCR9-targeted therapies for oncology.
Current CCR9 antibody development faces challenges, including ensuring receptor specificity and minimizing off-target effects. Preclinical studies and early-phase clinical trials have shown promise, but further optimization of pharmacokinetics and safety profiles is needed. Emerging technologies, such as humanized monoclonal antibodies and bispecific designs, may enhance therapeutic efficacy. Overall, CCR9 antibodies represent a versatile strategy for addressing inflammation, autoimmunity, and cancer, though translation to clinical practice requires deeper mechanistic insights and validation.
×
